Peter I. Karachunski

Peter I. Karachunski

Neuromusculoskeletal Medicine | Neurology | Pediatric Neurology

2512 South 7th Street
Floor 3
Minneapolis, MN 55454

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.

Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.

Journal: Journal of comparative effectiveness research

Published: August 22, 2025

Differences in swallowing efficacy of disease modifying treatment between infants receiving pre-symptomatic and symptomatic administration.

Differences in swallowing efficacy of disease modifying treatment between infants receiving pre-symptomatic and symptomatic administration.

Journal: Orphanet journal of rare diseases

Published: August 21, 2025

Reduction of Preexisting AAV9 Antibody Titers Before Onasemnogene Abeparvovec Administration in Twins With Spinal Muscular Atrophy.

Reduction of Preexisting AAV9 Antibody Titers Before Onasemnogene Abeparvovec Administration in Twins With Spinal Muscular Atrophy.

Journal: Neurology

Published: July 24, 2025

Long-Term Engraftment and Satellite Cell Expansion from Human PSC Teratoma-Derived Myogenic Progenitors.

Long-Term Engraftment and Satellite Cell Expansion from Human PSC Teratoma-Derived Myogenic Progenitors.

Journal: Cells

Published: July 04, 2025

Predicting the phenotype of Pompe Disease from features of GAA variants.

Predicting the phenotype of Pompe Disease from features of GAA variants.

Journal: European journal of human genetics : EJHG

Published: April 21, 2024

Systemic under treatment of heart disease in patients with Duchenne muscular dystrophy.

Systemic under treatment of heart disease in patients with Duchenne muscular dystrophy.

Journal: Neuromuscular disorders : NMD

Published: June 02, 2023

A comprehensive study of skeletal muscle imaging in FHL1-related reducing body myopathy.

A comprehensive study of skeletal muscle imaging in FHL1-related reducing body myopathy.

Journal: Annals of clinical and translational neurology

Published: February 07, 2023

Corrigendum to "Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy" [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502].

Corrigendum to "Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy" [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502].

Journal: Neuromuscular disorders : NMD

Published: January 16, 2021

Tetrahydrobiopterin synthesis and metabolism is impaired in dystrophin-deficient mdx mice and humans.

Tetrahydrobiopterin synthesis and metabolism is impaired in dystrophin-deficient mdx mice and humans.

Journal: Acta physiologica (Oxford, England)

Published: November 29, 2020

Anti-MDA5 juvenile idiopathic inflammatory myopathy with second-degree heart block but no skin or lung involvement: a case report.

Anti-MDA5 juvenile idiopathic inflammatory myopathy with second-degree heart block but no skin or lung involvement: a case report.

Journal: BMC rheumatology

Published: November 16, 2020

Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy.

Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy.

Journal: Journal of personalized medicine

Published: September 25, 2020

Nusinersen injections in adults and children with spinal muscular atrophy: a single-center experience.

Nusinersen injections in adults and children with spinal muscular atrophy: a single-center experience.

Journal: Diagnostic and interventional radiology (Ankara, Turkey)

Published: May 22, 2020

Showing 1-12 of 29

Last Updated: 09/26/2026